Exscientia ends cancer study as it focuses on other trials of AI-driven drug candidates
AI drug discovery and development company Exscientia is stopping a solid tumor trial as it refocuses its internal pipeline amid plans to ink another partnership deal “by the end of this year,” CEO Andrew Hopkins told Endpoints News.
The Oxford, UK-based biotech will end a Phase Ib/IIa trial of its oral capsule EXS21546 in combination with Bristol Myers Squibb’s Opdivo, Exscientia said Tuesday morning. The company said it will explore potential partnerships for follow-up compounds it created for the A2A mechanism, noting “it will be challenging for ‘546 to reach a suitable therapeutic index.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.